Spots Global Cancer Trial Database for A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
Official Title: CABONEN - A Phase II Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
Study ID: NCT04524208
Interventions
Study Description
Brief Summary: The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Medizinische Universität Wien, Wien, , Austria
University Medical Center Göttingen, Göttingen, Lower Saxony, Germany
Zentralklinik Bad Berka GmbH, Bad Berka, , Germany
Universitätsklinikum Carl Gustav Carus, Dresden, , Germany
Universitätsklinikum Erlangen, Erlangen, , Germany
Universitätsklinikum Freiburg, Freiburg, , Germany
Universitätsklinikum Halle, Halle, , Germany
Asklepios St. Georg, Hamburg, , Germany
Medizinische Hochschule Hannover, Hannover, , Germany
Klinikum Heidelberg, Heidelberg, , Germany
Universitätsmedizin Mannheim, Mannheim, , Germany
Universitätsklinikum Gießen und Marburg GmbH, Marburg, , Germany
Johannes-Wesling-Klinikum Minden, Minden, , Germany
Klinikum Ulm, Ulm, , Germany
Universitätsklinik Würzburg, Würzburg, , Germany
Contact Details
Name: Alexander König, PD Dr.
Affiliation: University Medical Center Göttingen
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
